Precision Strikes: KRAS-G12D, RET & TRK Therapies Post Record ORRs and ctDNA Proves the Earliest Truth-Teller

Targeted drugs stole the show: KRAS-G12D inhibitors shrank pancreatic tumors in >50% of patients, RET and NTRK blockers logged 40-70% response rates across rare fusions, and HER2-selective TKIs hit 70% in mutant lung cancer. The message is unmistakable—every high-risk patient needs broad genomic and emerging proteomic profiling to find these actionable needles.

Meanwhile, serial liquid-biopsy readouts of circulating tumor DNA cleared ≥50% within weeks on immunotherapy, outpacing scans as the clearest sign of durable benefit (or looming resistance).

Put together, the future of response assessment looks blood-based, fast, and firmly tied to precision medicine.